Genmab Regains Rights to HuMax-TAC

Genmab A/S has announced that it has regained all rights to the HuMax-TAC antibody from Merck Serono following a portfolio review by Merck Serono. Worldwide rights to HuMax-TAC were previously licensed to Merck Serono in May 2005.

HuMax-TAC is a human antibody that targets the TAC antigen, also known as CD25 or the interleukin-2 receptor alpha subunit, which is over-expressed by activated T-cells. By inhibiting the proliferation of T-cells, HuMax-TAC may have therapeutic potential in the treatment of T-cell mediated diseases, such as autoimmune disorders, inflammatory and hyperproliferative skin disorders, as well as acute transplant rejection.

For further information please contact:

Helle Husted,

Director Investor Relations

Tel: +45 33 44 77 30

Email: hth@genmab.com

Or visit: www.genmab.com

Home > News & Events > News > Genmab Regains Rights to HuMax-TAC
Last updated: 2007-08-04

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

GENMAB A/S

GENMAB A/S

Genmab A/S (CSE: GEN) is a global biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions,...